Similarly, TILs from patients with HNSCC (head and neck squamous cell cancers) refractory to anti-PD-1 therapy demonstrated an enhanced exhaustion phenotype with TIM-3 upregulation that appears to be mediated by PI3K-Akt pathway activity (218). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.